Cyanotic heart defect medical therapy

Revision as of 19:52, 18 October 2012 by Kalsang Dolma (talk | contribs)
Jump to navigation Jump to search

Cyanotic heart defect Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cyanotic heart defect from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cyanotic heart defect medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cyanotic heart defect medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cyanotic heart defect medical therapy

CDC on Cyanotic heart defect medical therapy

Cyanotic heart defect medical therapy in the news

Blogs on Cyanotic heart defect medical therapy

Directions to Hospitals Treating Cyanotic heart defect

Risk calculators and risk factors for Cyanotic heart defect medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor(s)-In-Chief: Keri Shafer, M.D. [2], Atif Mohammad, M.D.

Overview

Medical Therapy

Pharmacotherapy

Acute Pharmacotherapies

Infants that remain in the hospital may receive medicines to:

  • Get rid of extra fluids
  • Help the heart pump harder
  • Treat abnormal heartbeats or rhythms
  • In infants with severe polycythemia (>70 percent), an isovolumetric partial exchange transfusion should be performed with saline to reduce the hematocrit
  • Prostaglandin E1 (alprostadil) — Administered in infants with clinical suspicion of ductal-dependent congenital heart defect until a definitive diagnosis or treatment is established.

References


Template:WikiDoc Sources